Quanterix Company (QTRX) got here out with a quarterly lack of $0.67 per share consistent with the Zacks Consensus Estimate. This compares to a lack of $0.33 per share a 12 months in the past. These figures are adjusted for non-recurring gadgets.
1 / 4 in the past, it was anticipated that this firm would put up a lack of $0.67 per share when it truly produced a lack of $0.49, delivering a shock of 26.87%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates two instances.
Quanterix Company , which belongs to the Zacks Medical – Merchandise trade, posted revenues of $23.5 million for the quarter ended June 2022, lacking the Zacks Consensus Estimate by 20.45%. This compares to year-ago revenues of $25.37 million. The corporate has topped consensus income estimates 3 times during the last 4 quarters.
The sustainability of the inventory’s instant value motion primarily based on the recently-released numbers and future earnings expectations will principally rely on administration’s commentary on the earnings name.
Quanterix Company shares have misplaced about 58.8% for the reason that starting of the 12 months versus the S&P 500’s decline of -13%.
What’s Subsequent for Quanterix Company?
Whereas Quanterix Company has underperformed the market to this point this 12 months, the query that involves traders’ minds is: what’s subsequent for the inventory?
There aren’t any simple solutions to this key query, however one dependable measure that may assist traders deal with that is the corporate’s earnings outlook. Not solely does this embrace present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified these days.
Empirical analysis reveals a robust correlation between near-term inventory actions and developments in earnings estimate revisions. Buyers can monitor such revisions by themselves or depend on a tried-and-tested score software just like the Zacks Rank, which has a formidable monitor document of harnessing the ability of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions pattern for Quanterix Company: combined. Whereas the magnitude and route of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out consistent with the market within the close to future. You possibly can see the whole record of in the present day’s Zacks #1 Rank (Sturdy Purchase) shares right here.
It will likely be fascinating to see how estimates for the approaching quarters and present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.68 on $32.75 million in revenues for the approaching quarter and -$2.49 on $129.17 million in revenues for the present fiscal 12 months.
Buyers needs to be aware of the truth that the outlook for the trade can have a fabric impression on the efficiency of the inventory as effectively. When it comes to the Zacks Business Rank, Medical – Merchandise is at present within the backside 43% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
One different inventory from the identical trade, PetIQ (PETQ), is but to report outcomes for the quarter ended June 2022. The outcomes are anticipated to be launched on August 9.
This pet medicines and merchandise maker is anticipated to put up quarterly earnings of $0.35 per share in its upcoming report, which represents a year-over-year change of -46.2%. The consensus EPS estimate for the quarter has remained unchanged during the last 30 days.
PetIQ’s revenues are anticipated to be $259.28 million, down 4.3% from the year-ago quarter.
Need the newest suggestions from Zacks Funding Analysis? Immediately, you’ll be able to obtain 7 Finest Shares for the Subsequent 30 Days. Click on to get this free report
Quanterix Company (QTRX) : Free Inventory Evaluation Report
PetIQ, Inc. (PETQ) : Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
